Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.
Also called NCT06548204
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 160 participants
- Registry
-
NCT06548204
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06548204. Randomized; triple masking; primary purpose treatment. Start 2025-01-20 (actual); primary completion 2026-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
- Acronym
- FEND-AMI
- Condition
- ST-segment Elevation Myocardial Infarction (STEMI)
- Intervention (Drug)
- Fexofenadine Hydrochloride
- Intervention (Other)
- Placebo
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Record details
- Record id
cardio:ct-nct06548204- Content hash
ff3e21c473dbd28e3a4324862ab682c7827148ae44273b39b390bd266100f1f5